Cambridge, United Kingdom

David Lowne

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 10.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: David Lowne: Innovator in Antibody Research

Introduction

David Lowne is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting amyloid beta peptides. With a total of 5 patents to his name, Lowne's work is crucial in addressing conditions associated with amyloidosis, including Alzheimer's disease.

Latest Patents

David Lowne's latest patents focus on antibodies that selectively bind to human amyloid beta 42 peptide over human amyloid beta 40 peptide. These antibodies are designed as therapeutic agents for binding amyloid beta 42 peptide, which is essential in treating conditions related to amyloidosis. His innovative approach aims to provide new avenues for the treatment of Alzheimer's disease, showcasing his commitment to advancing medical science.

Career Highlights

Lowne is currently associated with Medimmune Limited, where he continues to push the boundaries of antibody research. His work has garnered attention for its potential impact on therapeutic strategies for neurodegenerative diseases. The innovative nature of his patents reflects his dedication to improving patient outcomes through scientific advancements.

Collaborations

David Lowne collaborates with talented professionals in his field, including Maria Groves and Suzanne Gustavsson. These partnerships enhance the research environment and contribute to the development of groundbreaking therapies.

Conclusion

David Lowne's contributions to antibody research are noteworthy and have the potential to significantly impact the treatment of Alzheimer's disease. His innovative patents and collaborations highlight his role as a leading inventor in the biotechnology sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…